197 related articles for article (PubMed ID: 29523661)
1. Idelalisib and Rituximab in 17p Deletion-Positive Splenic Marginal Zone Lymphoma.
Philip AZ
J Natl Compr Canc Netw; 2018 Mar; 16(3):230-233. PubMed ID: 29523661
[TBL] [Abstract][Full Text] [Related]
2. Aggressive variant of splenic marginal zone lymphoma characterized using a cancer panel test and treated with rituximab-containing chemotherapy: A case report.
Ishiguro K; Sasaki Y; Takagi Y; Niinuma T; Suzuki H; Tokino T; Hayashi T; Takahashi T; Igarashi T; Matsuno Y
Medicine (Baltimore); 2020 Aug; 99(35):e21938. PubMed ID: 32871937
[TBL] [Abstract][Full Text] [Related]
3. Splenic marginal zone lymphoma: from genetics to management.
Arcaini L; Rossi D; Paulli M
Blood; 2016 Apr; 127(17):2072-81. PubMed ID: 26989207
[TBL] [Abstract][Full Text] [Related]
4. Splenic marginal zone lymphoma: characterization of 7q deletion and its value in diagnosis.
Watkins AJ; Huang Y; Ye H; Chanudet E; Johnson N; Hamoudi R; Liu H; Dong G; Attygalle A; McPhail ED; Law ME; Isaacson PG; de Leval L; Wotherspoon A; Du MQ
J Pathol; 2010 Mar; 220(4):461-74. PubMed ID: 20077527
[TBL] [Abstract][Full Text] [Related]
5. Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma Group.
Salido M; Baró C; Oscier D; Stamatopoulos K; Dierlamm J; Matutes E; Traverse-Glehen A; Berger F; Felman P; Thieblemont C; Gesk S; Athanasiadou A; Davis Z; Gardiner A; Milla F; Ferrer A; Mollejo M; Calasanz MJ; Florensa L; Espinet B; Luño E; Wlodarska I; Verhoef G; García-Granero M; Salar A; Papadaki T; Serrano S; Piris MA; Solé F
Blood; 2010 Sep; 116(9):1479-88. PubMed ID: 20479288
[TBL] [Abstract][Full Text] [Related]
6. Splenic marginal zone lymphoma: excellent outcomes in 64 patients treated in the rituximab era.
Starr AG; Caimi PF; Fu P; Massoud MR; Meyerson H; Hsi ED; Mansur DB; Cherian S; Cooper BW; De Lima MJG; Lazarus HM; Gerson SL; Jagadeesh D; Smith MR; Dean RM; Pohlman BL; Hill BT; William BM
Hematology; 2017 Aug; 22(7):405-411. PubMed ID: 28105889
[TBL] [Abstract][Full Text] [Related]
7. Splenic marginal zone lymphoma with a de novo t(8;14)(q24;q32) and a prolymphocytoid evolution responsive to rituximab-bendamustine.
Scapinello G; Pizzi M; Vio S; Nabergoj M; Visentin A; Martines A; Bonaldi L; Trentin L; Semenzato G; Piazza F
Ann Hematol; 2018 Oct; 97(10):2001-2003. PubMed ID: 29728736
[No Abstract] [Full Text] [Related]
8. Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study.
Iannitto E; Bellei M; Amorim S; Ferreri AJM; Marcheselli L; Cesaretti M; Haioun C; Mancuso S; Bouabdallah K; Gressin R; Tripodo C; Traverse-Glehen A; Baseggio L; Zupo S; Stelitano C; Castagnari B; Patti C; Alvarez I; Liberati AM; Merli M; Gini G; Cabras MG; Dupuis J; Tessoulin B; Perrot A; Re F; Palombi F; Gulino A; Zucca E; Federico M; Thieblemont C
Br J Haematol; 2018 Dec; 183(5):755-765. PubMed ID: 30407629
[TBL] [Abstract][Full Text] [Related]
9. Treatment of splenic marginal zone lymphoma: splenectomy versus rituximab.
Bennett M; Schechter GP
Semin Hematol; 2010 Apr; 47(2):143-7. PubMed ID: 20350661
[TBL] [Abstract][Full Text] [Related]
10. Splenic marginal zone lymphoma with monoclonal IgG: A case report.
Zhang X; Ren S; Zhang N; Wang X; Qiu L; Sun H; Yi H; Fan F
Medicine (Baltimore); 2024 Feb; 103(6):e37158. PubMed ID: 38335376
[TBL] [Abstract][Full Text] [Related]
11. Bone marrow histopathology in the diagnostic evaluation of splenic marginal-zone and splenic diffuse red pulp small B-cell lymphoma: a reliable substitute for spleen histopathology?
Ponzoni M; Kanellis G; Pouliou E; Baliakas P; Scarfò L; Ferreri AJ; Doglioni C; Bikos V; Dagklis A; Anagnostopoulos A; Ghia P; Stamatopoulos K; Papadaki T
Am J Surg Pathol; 2012 Nov; 36(11):1609-18. PubMed ID: 23073320
[TBL] [Abstract][Full Text] [Related]
12. How to treat splenic marginal zone lymphoma (SMZL) in patients unfit for surgery or more aggressive therapies: experience in 30 cases.
Cervetti G; Ghio F; Cecconi N; Morganti R; Galimberti S; Petrini M
J Chemother; 2017 Apr; 29(2):126-129. PubMed ID: 27454143
[TBL] [Abstract][Full Text] [Related]
13. [Splenic marginal zone lymphoma complicated by cold agglutinin disease].
Ochi K; Yokoyama K; Ohno N; Ota Y; Tojo A
Rinsho Ketsueki; 2017; 58(2):132-137. PubMed ID: 28321090
[TBL] [Abstract][Full Text] [Related]
14. CD5 expression identifies a subset of splenic marginal zone lymphomas with higher lymphocytosis: a clinico-pathological, cytogenetic and molecular study of 24 cases.
Baseggio L; Traverse-Glehen A; Petinataud F; Callet-Bauchu E; Berger F; Ffrench M; Couris CM; Thieblemont C; Morel D; Coiffier B; Salles G; Felman P
Haematologica; 2010 Apr; 95(4):604-12. PubMed ID: 20015887
[TBL] [Abstract][Full Text] [Related]
15. Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: a Fondazione Italiana Linfomi phase II study.
Iannitto E; Luminari S; Tripodo C; Mancuso S; Cesaretti M; Marcheselli L; Merli F; Stelitano C; Carella AM; Fragasso A; Montechiarello E; Ricciuti G; Pulsoni A; Paulli M; Franco V; Federico M
Leuk Lymphoma; 2015; 56(12):3281-7. PubMed ID: 25791121
[TBL] [Abstract][Full Text] [Related]
16. First-line treatment with bendamustine and rituximab, in patients with intermediate-/high-risk splenic marginal zone lymphomas.
Castelli R; Bergamaschini L; Deliliers GL
Med Oncol; 2017 Dec; 35(2):15. PubMed ID: 29288421
[TBL] [Abstract][Full Text] [Related]
17. Significant efficacy of 2-chlorodeoxyadenosine{+/-} rituximab in the treatment of splenic marginal zone lymphoma (SMZL): extended follow-up.
Cervetti G; Galimberti S; Pelosini M; Ghio F; Cecconi N; Petrini M
Ann Oncol; 2013 Sep; 24(9):2434-8. PubMed ID: 23712547
[TBL] [Abstract][Full Text] [Related]
18. Clinico-biological features and outcome of patients with splenic marginal zone lymphoma with histological transformation.
Bastidas-Mora G; Beà S; Navarro A; Gine E; Costa D; Delgado J; Baumann T; Magnano L; Rivas-Delgado A; Villamor N; Colomer D; Lopez-Guerra M; Rozman M; Balagué O; Martínez D; Baptista MJ; Escoda L; Alcoceba M; Blanes M; Climent F; Campo E; Wotherspoon A; López-Guillermo A; Matutes E
Br J Haematol; 2022 Jan; 196(1):146-155. PubMed ID: 34519021
[TBL] [Abstract][Full Text] [Related]
19. Employment of oligodeoxynucleotide plus interleukin-2 improves cytogenetic analysis in splenic marginal zone lymphoma.
Bardi A; Cavazzini F; Rigolin GM; Tammiso E; Volta E; Pezzolo E; Formigaro L; Sofritti O; Daghia G; Ambrosio C; Rizzotto L; Abass AE; D'Auria F; Musto P; Cuneo A
J Biomed Biotechnol; 2011; 2011():691493. PubMed ID: 21629757
[TBL] [Abstract][Full Text] [Related]
20. Improved biological insight and influence on management in indolent lymphoma. Talk 3: update on nodal and splenic marginal zone lymphoma.
Thieblemont C
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):371-378. PubMed ID: 29222281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
